Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Schizophr Res. 2018 Apr;194:26-31. doi: 10.1016/j.schres.2017.05.004. Epub 2017 May 6.
Although people diagnosed with schizophrenia are known to have elevated risks of abuse and dependence for nicotine, alcohol, cocaine, and cannabis, it is less clear if schizophrenia is associated with higher rates of opioid use disorders compared to either the general population or individuals with other major psychiatric disorders. Here we examine a large publicly available database from substance abuse treatment centers to compare how frequently patients with schizophrenia report problems with heroin or other opioid drugs compared to other major drugs of abuse. For comparison, the pattern of substance abuse in schizophrenia is contrasted with individuals with major depression, bipolar disorder, and the entire sample of individuals seeking substance abuse treatment. We find that a significantly lower proportion of patients with schizophrenia are reported to have problems with heroin (5.1%) relative to the entire treatment population (18.2%). The schizophrenia sample also had a significantly lower proportion of individuals with a non-heroin opioid problem (7.2%) compared to the entire treatment population (14.8%), patients with depression (23%), and patients with bipolar disorder (17.3%). In contrast, the schizophrenia sample had significantly higher proportions of individuals with problems with alcohol, cocaine, and cannabis relative to the treatment population. Although these data do not allow conclusions on the relative rate of opioid addiction in schizophrenia compared to the general population, the results suggest a discrepancy in patterns of drug choice that may aid our understanding of schizophrenia and substance use comorbidity.
虽然已知诊断为精神分裂症的人对尼古丁、酒精、可卡因和大麻的滥用和依赖风险升高,但与普通人群或其他主要精神疾病患者相比,精神分裂症是否与更高的阿片类药物使用障碍率相关尚不清楚。在这里,我们检查了一个来自药物滥用治疗中心的大型公开可用数据库,以比较精神分裂症患者报告的海洛因或其他阿片类药物问题的频率与其他主要滥用药物的频率。为了进行比较,我们将精神分裂症中的物质滥用模式与患有重度抑郁症、双相情感障碍的个体以及寻求物质滥用治疗的所有个体进行了对比。我们发现,报告有海洛因问题的精神分裂症患者比例(5.1%)明显低于整个治疗人群(18.2%)。与整个治疗人群(14.8%)、抑郁症患者(23%)和双相情感障碍患者(17.3%)相比,精神分裂症患者中没有海洛因阿片类药物问题的比例也明显较低(7.2%)。相比之下,精神分裂症患者中报告有酒精、可卡因和大麻问题的比例明显高于治疗人群。尽管这些数据不能得出精神分裂症与普通人群相比阿片类药物成瘾的相对比率的结论,但结果表明药物选择模式存在差异,这可能有助于我们理解精神分裂症和物质使用共病。